Date: 2018-02-26
Type of information: Nomination
Compound: head of patient access and commercial planning
Company: Mereo Biopharma (UK)
Therapeutic area: Rare diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On February 26, 2018 Mereo BioPharma announced the appointment of Wills Hughes-Wilson as Head of Patient Access and Commercial Planning. In her role, Ms. Hughes-Wilson will be responsible for leading and optimizing Mereo’s patient access and commercialization strategies, initially in a part-time role as the company builds out its rare disease commercial infrastructure.
- Most recently, Ms. Hughes-Wilson served on the Executive Leadership Team as Chief Patient Access Officer and Senior Vice President Access & External Affairs at Swedish Orphan Biovitrum (Sobi), an international specialty healthcare company dedicated to rare diseases. In her role, Ms. Hughes-Wilson was responsible for Sobi’s go-to-market commercialization approach and led the pricing, reimbursement and access teams for Sobi’s rare disease product portfolio. Prior to joining Sobi, Ms. Hughes-Wilson served as Vice President of Health and Market Access Policy at Genzyme Corporation (now part of Sanofi).
Financial terms:
Latest news:
Is general: Yes
